Italian Multicenter Observational Study on Real-Life Experience with Alemtuzumab in Naïve Patients with Aggressive Multiple Sclerosis

Alemtuzumab (ALEM) is an anti-CD52 monoclonal antibody approved for the treatment of active Multiple Sclerosis(MS) which showed high efficacy also in the subgroup of highly-active patients. We aimed to evaluate efficacy/safety profile of ALEM-treatment in a population of aggressive MS naïve-patients.